PriceTargets.com logo

Kodiak Sciences - KOD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $48.14
  • Forecasted Upside: 47.05%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$32.74 As of 09/15/2026 11:48 AM ET
▼ -0.4 (-1.21%)

This chart shows the closing price for KOD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kodiak Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KOD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KOD

Analyst Price Target is $48.14
▲ +47.05% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $48.14, with a high forecast of $80.00 and a low forecast of $15.00. The average price target represents a 47.05% upside from the last price of $32.74.

This chart shows the closing price for KOD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Kodiak Sciences. This rating has held steady since December 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/15/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/14/2026

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/17/2026HC WainwrightReiterated RatingBuy ➝ Buy$58.00
8/3/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$56.00 ➝ $66.00
7/10/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
5/11/2026Chardan CapitalUpgradeNeutral ➝ Buy$14.00 ➝ $61.00
3/27/2026UBS GroupBoost TargetBuy ➝ Buy$50.00 ➝ $80.00
3/27/2026HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $58.00
2/10/2026HC WainwrightReiterated RatingBuy ➝ Buy$38.00
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/22/2026HC WainwrightBoost TargetBuy ➝ Buy$26.00 ➝ $38.00
1/7/2026UBS GroupInitiated CoverageNeutral ➝ Buy$50.00
1/7/2026UBS GroupInitiated CoverageBuy$50.00
11/17/2025HC WainwrightBoost TargetBuy ➝ Buy$24.00 ➝ $26.00
11/17/2025Chardan CapitalReiterated RatingNeutral ➝ Neutral$14.00
11/11/2025HC WainwrightUpgradeNeutral ➝ Buy$5.00 ➝ $24.00
10/24/2025JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00 ➝ $24.00
10/23/2025Lifesci CapitalInitiated CoverageOutperform$40.00
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/6/2025Chardan CapitalReiterated RatingNeutral ➝ Neutral$14.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/25/2025BarclaysUpgradeUnderweight ➝ Equal Weight$7.00 ➝ $17.00
9/22/2025Jefferies Financial GroupInitiated CoverageBuy$15.00
8/18/2025HC WainwrightBoost TargetNeutral ➝ Neutral$3.00 ➝ $5.00
8/14/2025BarclaysBoost TargetUnderweight ➝ Underweight$4.00 ➝ $7.00
8/14/2025JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$15.00
3/31/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
12/9/2024Jefferies Financial GroupUpgradeHold ➝ Buy$20.00
11/15/2024BarclaysBoost TargetUnderweight ➝ Underweight$3.00 ➝ $4.00
11/15/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
9/24/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
9/5/2024HC WainwrightInitiated CoverageNeutral$3.00
4/4/2024UBS GroupBoost TargetNeutral ➝ Neutral$3.00 ➝ $5.00
4/1/2024BarclaysBoost TargetUnderweight ➝ Underweight$2.00 ➝ $3.00
12/21/2023UBS GroupLower TargetNeutral ➝ Neutral$4.00 ➝ $3.00
12/11/2023The Goldman Sachs GroupReiterated RatingSell$2.00
11/17/2023Capital One FinancialUpgradeEqual Weight ➝ Overweight$7.00 ➝ $12.00
7/27/2023UBS GroupDowngradeBuy ➝ Neutral$15.00 ➝ $4.00
7/25/2023Chardan CapitalDowngradeBuy ➝ Neutral
7/24/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
7/24/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
7/24/2023Capital One FinancialDowngradeOverweight ➝ Equal Weight$7.00
4/4/2023JPMorgan Chase & Co.Lower TargetNeutral$12.00 ➝ $10.00
11/15/2022Capital One FinancialInitiated CoverageOverweight$24.00
11/14/2022Morgan StanleyLower TargetEqual Weight$12.00 ➝ $9.00
11/10/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $8.00
11/10/2022CitigroupLower Target$8.00 ➝ $6.00
8/15/2022Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $12.00
8/10/2022Chardan CapitalLower TargetBuy$19.00 ➝ $18.00
8/9/2022Truist FinancialBoost TargetBuy$10.00 ➝ $15.00
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$9.00
8/2/2022CitigroupDowngradeNeutral ➝ Sell
4/12/2022Morgan StanleyLower TargetEqual Weight$17.00 ➝ $12.00
4/11/2022Chardan CapitalReiterated RatingBuy
3/29/2022Chardan CapitalLower Target$82.50 ➝ $19.00
2/28/2022Roth CapitalLower Target$149.00 ➝ $75.00
2/24/2022Truist FinancialLower Target$147.00 ➝ $35.00
2/24/2022Morgan StanleyLower TargetEqual Weight$77.00 ➝ $17.00
2/24/2022CitigroupLower TargetNeutral$70.00 ➝ $12.00
2/24/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$90.00 ➝ $21.00
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$70.00
2/7/2022BarclaysLower TargetUnderweight$81.00 ➝ $50.00
2/2/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$124.00 ➝ $90.00
2/1/2022Morgan StanleyLower TargetEqual Weight$122.00 ➝ $77.00
1/26/2022CitigroupLower TargetNeutral$114.00 ➝ $70.00
1/18/2022Morgan StanleyBoost TargetEqual Weight$119.00 ➝ $122.00
11/12/2021BMO Capital MarketsBoost TargetMarket Perform$104.00 ➝ $114.00
11/11/2021CitigroupBoost TargetNeutral$103.00 ➝ $114.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

1.24 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 11 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 16 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 16 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Kodiak Sciences logo
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Read More

Today's Range

Now: $32.74
Low: $32.50
High: $33.29

50 Day Range

MA: $39.83
Low: $32.87
High: $45.40

52 Week Range

Now: $32.74
Low: $9.10
High: $47.84

Volume

108,872 shs

Average Volume

823,506 shs

Market Capitalization

$2.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Kodiak Sciences?

The following Wall Street research analysts have issued research reports on Kodiak Sciences in the last twelve months: Barclays PLC, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Lifesci Capital, UBS Group AG, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for KOD.

What is the current price target for Kodiak Sciences?

0 Wall Street analysts have set twelve-month price targets for Kodiak Sciences in the last year. Their average twelve-month price target is $48.14, suggesting a possible upside of 45.3%. UBS Group AG has the highest price target set, predicting KOD will reach $80.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $15.00 for Kodiak Sciences in the next year.
View the latest price targets for KOD.

What is the current consensus analyst rating for Kodiak Sciences?

Kodiak Sciences currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KOD.

What other companies compete with Kodiak Sciences?

Other companies that are similar to Kodiak Sciences include ImmunityBio, TG Therapeutics, Apogee Therapeutics, Immunovant and Spyre Therapeutics. Learn More about companies similar to Kodiak Sciences.

How do I contact Kodiak Sciences' investor relations team?

Kodiak Sciences' physical mailing address is 1250 Page Mill RD, Palo Alto, CA, 94304. The company's listed phone number is (650) 281-0850 and its investor relations email address is [email protected]. The official website for Kodiak Sciences is kodiak.com. Learn More about contacing Kodiak Sciences investor relations.